GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » PE Ratio (TTM)
中文

Intelgenx Technologies (Intelgenx Technologies) PE Ratio (TTM) : At Loss (As of Apr. 24, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Intelgenx Technologies PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-24), Intelgenx Technologies's share price is $0.15. Intelgenx Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.06. Therefore, Intelgenx Technologies's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Intelgenx Technologies's PE Ratio (TTM) or its related term are showing as below:

IGXT' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 35.33   Max: 98.33
Current: At Loss


During the past 13 years, the highest PE Ratio (TTM) of Intelgenx Technologies was 98.33. The lowest was 0.00. And the median was 35.33.


IGXT's PE Ratio (TTM) is ranked worse than
100% of 251 companies
in the Biotechnology industry
Industry Median: 27.12 vs IGXT: At Loss

Intelgenx Technologies's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.01. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.06.

As of today (2024-04-24), Intelgenx Technologies's share price is $0.15. Intelgenx Technologies's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.06. Therefore, Intelgenx Technologies's PE Ratio without NRI for today is At Loss.

During the past 13 years, Intelgenx Technologies's highest PE Ratio without NRI was 98.33. The lowest was 0.00. And the median was 35.33.

Intelgenx Technologies's EPS without NRI for the three months ended in Dec. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.06.

During the past 3 years, the average EPS without NRI Growth Rate was 1.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.40% per year.

During the past 13 years, Intelgenx Technologies's highest 3-Year average EPS without NRI Growth Rate was 29.10% per year. The lowest was -115.40% per year. And the median was 1.40% per year.

Intelgenx Technologies's EPS (Basic) for the three months ended in Dec. 2023 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.06.


Intelgenx Technologies PE Ratio (TTM) Historical Data

The historical data trend for Intelgenx Technologies's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies PE Ratio (TTM) Chart

Intelgenx Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Intelgenx Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Intelgenx Technologies's PE Ratio (TTM)

For the Biotechnology subindustry, Intelgenx Technologies's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelgenx Technologies's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's PE Ratio (TTM) falls into.



Intelgenx Technologies PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Intelgenx Technologies's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.15/-0.060
=At Loss

Intelgenx Technologies's Share Price of today is $0.15.
Intelgenx Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Intelgenx Technologies  (OTCPK:IGXT) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Intelgenx Technologies PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelgenx Technologies (Intelgenx Technologies) Business Description

Traded in Other Exchanges
Address
6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.
Executives
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian officer: VP, Finance&Admin - Subsidiary 4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham officer: CEO 15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel officer: SVP, Corp. Dev&SA - Subsidiary 23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe 10 percent owner, officer: Chief Executive Officer 714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin officer: CFO 440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny officer: VP IP,Lgl Affairs - Subsidiary 88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen officer: VP Business+Corp. Development 4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe 10 percent owner, officer: Corporate Secretary 714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid officer: Vice President, Operations 4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau director 2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham officer: Vice President Manufacturing 102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki director 118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard officer: VP Corporate Development 141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4